← All trials
NCT07145736
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 4, 2025
- Primary completion
- Mar 31, 2029
- Completion date
- Jun 30, 2029
- First posted
- Aug 28, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 52000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- World Health OrganizationCollaborator
- University of OttawaCollaborator
- Erasmus University RotterdamCollaborator
- Medicines Development for Global HealthCollaborator
- University of BaselCollaborator
- The Mentor InitiativeCollaborator
- Emory UniversityCollaborator
- Murdoch UniversityCollaborator
- University of MelbourneCollaborator
- La Trobe UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.